Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Abstract
Recent preclinical data suggest that cyclin-dependent kinase 4/6 (CDK4/6) inhibition may be harnessed to sensitize estrogen receptor–positive (ER+) breast cancer to radiotherapy. However, these findings were obtained in human ER+ breast cancer cell lines exposed to subclinical doses of CDK4/6 inhibitors with limited attention to treatment schedule. We investigated the activity of radiotherapy combined with the prototypic CDK4/6 inhibitor palbociclib placing emphasis on therapeutic schedule.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 25, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3871
Entities
People
- Aitziber Buqué
- Giulia Petroni
- Lorenzo Galluzzi
- Maurizio Di Liberto
- Norma Bloy
- Selina Chen-kiang
- Silvia C. Formenti
- Takahiro Yamazaki
Organizations
- Leukemia & Lymphoma Society
- National Institutes of Health
- Weill Cornell Medicine